Project from Weyergangs project group admitted to SPARK Norway

In the project entitled "A Novel Biomarker for Antibody Drug Conjugates" Weyergang and her team seeks to develop a diagnostic tool for better stratification of patients to novel targeted therapeutics including antibody drug conjugates.

SPARK is a Life Science`s innovation program build to increase the success rate of projects with high potential impact, addressing critical unmet needs. Project teams admitted to SPARK will be educated and advised on relevant processes for commercialization of their idea. They will also receive financial support (up to 500 000 NOK per year- maximum two years based on the accomplishment of milesones).